Five-year study draws to an end after recruiting over 30,000 aspirin users across primary care. The study, known as HEAT, was funded and supported by the National Institute for Health Research (NIHR) and closed last month after recruiting patients over a five year period. Due to the large number of participants that needed to be recruited, the study was delivered with the involvement of 1,260 general practices across the UK.
My name is Geoff Robson. Having retired after working in the rail industry for 40 years, I wanted to be involved in some form of voluntary work within the NHS.
Having been involved with my local Patient Participation Group, I became aware of the Clinical Research Network and was asked if I would be interested in becoming a Patient Research Ambassador.
There have been some recent changes to the contractual requirements that must be in place by October 2018 to enable the LCRN to provide funding or resource to organisations to directly support the delivery of National Institute of Health Research (NIHR) portfolio research.
In order to comply with the host contract, we will be issuing a DHSC approved contract, described as a "Partner B" or "Partner C" contract.
Do you see teenagers with fatigue? They may come to your surgery with recurrent headaches or abdominal pain, nausea and dizziness. If the fatigue has lasted longer than three months and it is preventing them doing things, they may have Chronic Fatigue Syndrome or CFS/ME.
An estimated 2.5 million people in the UK are cancer ‘survivors’ (people who have finished primary treatment for cancer, whether or not they are cured) with this number on the increase. Anxiety and depression are common within this population as are fatigue and lack of physical activity. Studies show that healthy lifestyle changes and support for improving psychological wellbeing could improve quality of life for cancer survivors.
ATTACK (ASPIRIN TO TARGET ARTERIAL EVENTS IN CHRONIC KIDNEY DISEASE) is a pragmatic multicentre open-label randomised controlled trial to determine whether the addition of low-dose aspirin to usual care reduces the risk of major vascular events in people with chronic kidney disease (CKD) who do not have pre-existing cardiovascular disease (CVD).